A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process-Reference-Cited by-同舟云学术

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

Published:2010-03 Issue:6 Volume:148 Page:961-963
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Barosi Giovanni,Birgegard Gunnar,Finazzi Guido,Griesshammer Martin,Harrison Claire,Hasselbalch Hans,Kiladijan Jean-Jacques,Lengfelder Eva,Mesa Ruben,Mc Mullin Mary F.,Passamonti Francesco,Reilly John T.,Vannucchi Alessandro M.,Barbui Tiziano

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.08019.x/fullpdf

Reference10 articles.

1. When and how to treat essential thrombocythemia;Barbui;New England Journal of Medicine,2005

2. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET);Barosi;Blood,2005

3. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group;Barosi;Leukemia,2007

4. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference;Barosi;Blood,2009

5. Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy;Christoforidou;Acta Haematologica,2008

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.);Clinical Oncohematology;2024-07-01

2. Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice;Journal of Clinical Medicine;2024-06-10

3. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia;American Journal of Hematology;2024-06-06

4. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment;Journal of Hematology;2024-04

5. Differences in Clinical Outcomes Between Hydroxyurea-Resistant and-Intolerant Polycythemia Vera Patients;J KOREAN MED SCI;2024